Filing Details

Accession Number:
0000899243-20-025364
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-09-16 18:35:12
Reporting Period:
2020-09-14
Accepted Time:
2020-09-16 18:35:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1731831 Eidos Therapeutics Inc. EIDX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1655016 C Jonathan Fox C/O Eidos Therapeutics, Inc.
101 Montgomery Street, Suite 2000
San Francisco CA 94104
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-09-14 111 $50.00 387,562 No 4 S Indirect See footnote
Common Stock Disposition 2020-09-15 1,000 $50.06 386,562 No 4 S Indirect See footnote
Common Stock Disposition 2020-09-16 3,122 $50.16 383,440 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 3,294 Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2020.
  2. The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014.
  3. Represents the weighted average sale price of the shares sold ranging from $50.00 to $50.11 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 and 4.
  4. Represents the weighted average sale price of the shares sold ranging from $50.015 to $50.36 per share.